A Comparison of Urine Dilution Ability between Adult Dominant Polycystic Kidney Disease, Other Chronic Kidney Diseases, and Healthy Control Subjects: A Case-Control Study

M. H. Malmberg, F. H. Mose, E. B. Pedersen, and J. N. Bech

University Clinic in Nephrology and Hypertension, Regional Hospital Jutland West, University of Aarhus, Aarhus, Denmark

Correspondence should be addressed to M. H. Malmberg; mymalmbe@rm.dk

Received 6 July 2020; Revised 10 November 2020; Accepted 19 November 2020; Published 3 December 2020

Academic Editor: Jaime Uribarri

Copyright © 2020 M. H. Malmberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The final dilution of urine is regulated via aquaporin-2 water channels in the distal part of the nephron. It is unclear whether urine dilution ability in autosomal dominant polycystic kidney disease patients (ADPKD patients) differs from other patients with similar degree of impaired renal function (non-ADPKD patients). The purpose of this case control study was to measure urine dilution ability in ADPKD patients compared to non-ADPKD patients and healthy controls.

Methods. Eighteen ADPKD, 16 non-ADPKD patients (both with chronic kidney disease, stage I-IV), and 18 healthy controls received an oral water load of 20 ml/kg body weight. Urine was collected in 7 consecutive periods. We measured free water clearance ($C_{\text{H}_2\text{O}}$), urine osmolality, urine output, fractional excretion of sodium, urine aquaporin2 (u-AQP2), and urine epithelial sodium channel (u-ENaC). Blood samples were drawn four times (at baseline, 2h, 4h, and 6 hours after the water load) for analyses of plasma osmolality, vasopressin, renin, angiotensin II, and aldosterone. Brachial and central blood pressure was measured regularly during the test.

Results. The three groups were age and gender matched, and the patient groups had similar renal function. One hour after water load, the ADPKD patients had an increased $C_{\text{H}_2\text{O}}$ compared to non-ADPKD patients ($2.97 \pm 2.42$ ml/min in ADPKD patients vs. $1.31 \pm 1.50$ ml/min in non-ADPKD patients, $p < 0.029$). The reduction in u-AQP2 and u-ENaC occurred earlier in ADPKD than in non-ADPKD patients. Plasma concentrations of vasopressin, renin, angiotensin II, and aldosterone and blood pressure measurements did not show any differences that could explain the deviation in urine dilution capacity between the patient groups.

Conclusions. ADPKD patients had a higher $C_{\text{H}_2\text{O}}$ than non-ADPKD patients after an oral water load, and u-AQP2 and u-ENaC were more rapidly reduced than in non-ADPKD patients. Thus, urine-diluting capacity may be better preserved in ADPKD patients than in non-ADPKD patients.

1. Introduction

The final dilution of the urine is regulated via vasopressin dependent aquaporin-2 water channels in the apical membrane of kidney principal cells [1–3]. The ability to dilute the urine can be measured by a urine diluting test, in which the participants undergo water loading [4]. Urine dilution is generally reduced in kidney diseases, but the severity and underlying mechanisms may deviate in different kidney disease [5].

Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disease with multiple cysts in the kidneys, leading to decline in kidney function [6]. Previous studies have shown that vasopressin stimulates the growth of kidney cysts and may be a significant factor in the pathogenesis and progression of ADPKD [7–10]. However, it is unclear whether urine dilution ability in ADPKD differs from other patients with similar degree of impaired renal function (non-ADPKD patients).

The purpose of the present case-control study was to perform a urine dilution test in patients with ADPKD (Group1), in patients with chronic kidney diseases without ADPKD (Group 2) and in healthy control subjects (Group 3). The three groups have previously participated in a water
deprivation test on another examination day, at least 10 days apart. The results have been published previously [11].

The mechanisms differ for development of decline in renal function in ADPKD from other kidney diseases. Thus, we hypothesized that ADPKD patients have a reduced urinary dilution ability compared to other patients with a similar degree of impaired kidney function (non-ADPKD patients) and compared to healthy controls. We also hypothesized that the difference in urine diluting ability between patients with chronic renal disease and healthy controls could be partly explained by change, in the vaso-active hormone systems or blood pressure.

2. Materials and Methods

2.1. Study Design. The design was as a randomized, case-control study with three groups. Group 1 comprised patients with ADPKD, Group 2 comprised patients with chronic kidney diseases other than ADPKD (non-ADPKD), and Group 3 comprised healthy control subjects. The subjects participated in two different examination days, at least 10 days apart. A water deprivation test on one day and a water loading test on the other were performed.

2.2. Recruitment. Participants were recruited in the period between September 2017 and November 2018. In Groups 1 and 2, patients were recruited from the Outpatient Clinic of Nephrology in University Clinic in Nephrology and Hypertension, Department of Medicine at Holstebro Hospital, Denmark. Healthy controls in Group 3 were recruited by advertising in the local newspaper. All three groups were matched regarding age and gender. The two patient groups were matched regarding eGFR, calculated by CKD-EPI formula.

2.3. Randomization. The website redcap.au.dk randomized the order in which the subjects participated in each examination day with altering block sizes.

2.4. Subjects

2.4.1. Inclusion Criteria

Group 1. Age 18 years or older: men and unfertile women or fertile women using safe contraception throughout the trial period (safe contraception is defined as birth control pills, spiral, depot injection of progestogen, subdermal implantation, hormonal vaginal ring, transdermal patch, sexual abstinence, or sterilization). Kidney function corresponds to chronic kidney disease (CKD) stages I-IV (eGFR >15 mL/min/1.73 m²). ADPKD was diagnosed by genetic testing for PKD1 and PKD2 mutations or presence of one of the following ultra-sonographic findings in accordance with the classic Ravine criteria. Thus, patients were included with a negative family history of ADPKD, when they had more than 10 cysts in each kidney without other causes of extrarenal or renal cyst formations. In addition, patients with a family history of ADPKD were included depending on age and number of cysts. The demand for inclusion was ≥3 cysts uni- or bilaterally in age 18–39 years, ≥2 cysts in each kidney in age 40–59 years, and ≥4 cysts in age higher than 60 years [12]. Group 2. Same criteria as for Group 1 but without the criteria for ADPKD. Group 3. Age 18 years or older. Healthy men and unfertile women or fertile women using safe contraception throughout the trial period (as indicated for Group 1).

2.4.2. Exclusion Criteria

Groups 1 and 2. Previous kidney transplantation or kidney operation, diabetes mellitus, lithium nephropathy, medullary cystic kidney disease, neoplastic disease, pregnancy or breastfeeding, withdrawn consent, intolerance to or unacceptable side effects to water loading test, alcohol or drug abuse, or blood pressure >170/110 mm Hg despite treatment with metoprolol and/or amlodipine. Group 3. Arterial hypertension, i.e., office blood pressure above 140 mm Hg systolic and/or 90 mm Hg diastolic, significant clinical signs of heart disease, diseases of the lungs, liver, kidneys, endocrine organs, brain or neoplastic disorders, alcohol or drug abuse, medical treatment except oral contraceptives, smoking, pregnancy, or breastfeeding, clinically significant abnormal findings in blood tests (plasma concentration of sodium, potassium, albumin, creatinine, bilirubin, albumin-a-tominino-transaminase (ALAT), alkaline phosphatase, cholesterol, calcium, phosphate, parathyroid hormone (PTH), thyroid-stimulating hormone (TSH), blood concentration of hemoglobin, leukocytes, platelets, and glycosylated hemoglobin A1c (HbA1c), or in the urine sample (leukocytes, nitrite, blood, glucose, and albumin), clinically significant changes in electrocardiogram, blood donation within the last month before the test date in the first trial sequence, and intolerance to or unacceptable side effects to water loading test.

2.4.3. Withdrawal Criteria. Development of exclusion criteria and serious or unacceptable side effects are the withdrawal criteria.

2.5. Effect Variables. The primary effect variable was free water clearance ($C_{\text{H}_{2}O}$). The secondary effect variables were (1) urine osmolality (u-Osm), urine output (UO), and fractional excretion of sodium (FE$_{\text{Na}}$); (2) urine excretion of aquaporin 2 water channels (u-AQP2) and urine excretion of a fraction of the epithelial sodium channels (u-ENaC); (3) plasma concentrations of vasopressin (p-AVP), renin (PRC), angiotensin II (p-AngII) and aldosterone (p-Aldo), and plasma osmolarity (p-Osm); (4) brachial and central blood pressure (bBP and cBP), augmentation index (AIx), and pulse wave velocity (PWV).

2.6. Number of Subjects. With a minimal relevant difference of 0.7 mL/min in $C_{\text{H}_{2}O}$ with an estimated standard deviation (SD) of 0.9 mL/min, 16 subjects were needed using a level of significance of 5% and a statistical power of 90%. To
counteract any drop out, 20 patients with ADPKD, 20 non-ADPKD patients, and 20 healthy subjects were included.

2.7. Antihypertensive Medications. Antihypertensive medications including diuretics, angiotensin-converting enzyme inhibitors, and angiotensin-II inhibitors were discontinued or substituted with metoprolol 25 mg and/or amiodipine 5 mg, one or two times a day 14 days prior to each test day. During the study period, BBP was monitored using a home blood pressure monitor. At a blood pressure of >170/110 mm Hg, metoprolol 25 mg and/or amiodipine 5 mg was given and increased up to metoprolol 100 mg and/or amiodipine 10 mg. Subjects were discontinued from the study if blood pressure above 170/110 mm Hg continued despite treatment with metoprolol tartrate or metoprolol succinate 100 mg and/or amiodipine 10 mg. The usual antihypertensive treatment was resumed immediately after the examination day ended.

2.8. Ethics. The Regional Committee on Health Research Ethics approved the study (case number: 1-10-72-147-17). The study was done in agreement with the Declaration of Helsinki and was registered at clinicaltrials.gov (identifier: NCT04363554). Written informed consent was obtained from each subject.

3. Experimental Procedure

The study took place at the Laboratory in the University Clinic in Nephrology and Hypertension, Regional Hospital Jutland West. On the day prior to the examination day, all participants arrived at the University Clinic in Nephrology and Hypertension from 07.30 AM the day before examination to 01.30 PM. After Period 2, the subjects received an oral water load of 20 ml/kg body weight during 20 minutes. Blood samples were drawn after each period. Urine samples were collected before the participants arrived at the University Clinic in Nephrology and Hypertension from 07.30 AM the day before examination to 07.30 AM on the examination day (Period 1). Thereafter, urine was collected in six consecutive periods (Periods 2–7) of each one-hour’s duration from 07.30 AM to 01.30 PM. After Period 2, the subjects received an oral water load of 20 ml/kg body weight during 20 minutes. Blood samples were drawn after each period. Urine samples were collected by voiding in standing or sitting position after blood samples had been collected. Patients were kept in a supine position in a quiet and temperature-controlled room (22–25°C). BBP and cBP were measured every 20 minutes by Mobil-O-Graph® PWA on one of the subject’s upper arm. In the other arm, an intravenous catheter was placed to collect blood samples. In urine, we measured UO, u-Osm, u-Na (urine sodium), u-Cr (urine creatinine), u-AQP2, u-ENaC, and u-Alb (urine albumin) in all samples. In plasma, we measured p-AVP, PRC, p-AngII, and p-Aldo after periods 2, 4, 6, and 7. After all periods, we measured p-Osm, p-Na (plasma sodium), p-Cr (plasma creatinine), and p-Alb (plasma albumin).

3.1. Measurements

3.1.1. Renal Function. Estimated GFR (eGFR) was calculated using the CKD-EPI formula. Clearance (C) of substance X was calculated as $C_X = \frac{U_X \times UO}{P_X}$, where $U_X$ denotes concentration of x in urine and $P_X$ denotes concentration of x in plasma and UO is urine excretion rate. $FE_{Na}$ was determined according to the following formula: $FE_{Na} = \frac{100 \times (u-Na \times p-Cr)/(p-Na \times u-Cr))$. Free water clearance was determined according to the following formula: $C_{H2O} = \frac{UO}{u-C_{osm}}$.

3.1.2. AQP2 and ENaC in Urine. Urine samples were kept frozen at −20°C until assayed. U-AQP2 was determined by RIA as described in details previously [13, 14]. AQP2 and rabbit anti-AQP2 antibodies were a gift from Professor Soren Nielsen and Professor Robert Fenton, the Water and Salt Research Center, Aarhus University, Denmark. Iodination of $ETA$ was performed by the chloramine $T$ method. Samples and standard were incubated during 24 hours, and then the tracer was added. After further 4 hours, the reaction was stopped by gamma globulin and polyethylene glycol. After centrifugation, the precipitate (bound fraction) was counted in a gamma counter. The minimal detection level was 32 pg/tube. Coefficients of variation: 11.7% (interassay) and 5.9% (intra-assay). $U$-$ENA_C$ was measured by RIA as described in details previously [15, 16]. $ENA_C$ was synthesized and purchased by Lofstrand, Gaithersburg, Maryland, USA. It is a protein and part of the epithelial sodium channel in the distal part of the nephron. The $ENA_C$ antibody was a gift from Professor Soren Nielsen and Professor Robert Fenton, the Water and Salt Center, Aarhus University. Iodination of $ENA_C$ was performed by the chloramine $T$ method. Samples and standard were incubated during 24 hours, and then the tracer was added. After further 4 hours of incubation, gammaglobulin and polyethylene glycol was added. The mixture was centrifuged, and the precipitate was counted in a gamma counter. The minimal detection level was 35 pg/tube. Coefficients of variation was 10% at a mean level of 338 pg/tube (inter-assay), 9 % at a mean level of 743 pg/tube (interassay), 5.0 % in the range 125–135 pg/tube (intra-assay), and 5.6 % in the range 290–380 pg/tube (intra-assay).

3.1.3. Vasoactive Hormones in Plasma. Blood samples for measurements of vasoactive hormones were centrifuged for 10 minutes at 2200 G and 4°C. Plasma was separated from blood cells and kept frozen until assayed. P-AVP and p-AngII were extracted from plasma with $C_{18}$ Sep-Pak (Waters Corporation, Milford, MA, USA) and determined by radioimmunoassay (RIA) as previously described [13, 14].
antibodies against AVP were a gift from Professor Jacques Dürr (Miami, FL, USA). The minimal detection level was 0.5 pmol/L. The coefficients of variation were 13% (inter-assay) and 9% (intra-assay). Antibodies against ANGII were obtained from the Department of Clinical Physiology, Glostrup Hospital, Denmark. The minimal detection level was 2 pmol/L. The coefficients of variation were 12% (inter-assay) and 8% (intra-assay). P-Aldo was determined by a RIA kit from Demeditec Diagnostics GmbH, Kiel, Germany. The minimal detection level was 14.8 pg/mL. The coefficients of variations were 10.2% (inter-assay) and 11.9% (intra-assay). PRC was determined by a RIA kit (CIS Bio International, Gif-Sur-Yvette Cedex, France). The minimal detection level was 1 pg/mL. The coefficients of variations were 4.1% (inter-assay) and 1.8% (intra-assay).

3.1.6. Statistics. Statistical analyses were performed using IBM SPSS statistics version 20 (SPSS Inc., Chicago, IL, USA). For comparison between and within the three groups, we used a general linear model with Greenhouse-Geisser correction for violating the assumption of sphericity with repeated-measures ANOVA. Data were tested for normal distribution. For comparison between two groups, we used a paired or unpaired t test, when data showed normal distribution. For data which did not show normal distribution, we used a Mann-Whitney U test for unpaired data and Wilcoxon’s signed rank test for paired data. Statistical significance was set at <0.05 in all analyses. Data with normal distribution are reported as mean ± SD, and data with non-normal distribution are reported as medians with 25% and 75% percentiles in brackets.

4. Results

4.1. Demographics. Baseline demographics and clinical characteristics are presented in Table 1. Twenty ADPKD patients with chronic kidney disease stages I–IV were allocated to the study. One patient was excluded due to problems with venepuncture. One patient was excluded due to withdrawal of consent. Thus, 18 patients were included in Group 1. Twenty non-ADPKD patients with CKD stages I–IV were allocated to the study. One patient was excluded due to side effects of the background antihypertensive medicine. Three patients were excluded due to withdrawal of consent. Thus, 16 patients were included in Group 2. Twenty healthy controls were included in the study. Two participants were excluded due to withdrawal of consent. Thus, 18 participants were included in Group 3.

All three groups had similar age (ADPKD patients had a median age of 53 years, non-ADPKD patients 56 years, healthy controls 57 years, p = 0.469 between ADPKD and non-ADPKD patients), but both patient groups had a lower eGFR compared to healthy controls (87 ± 13 ml/min/1.73 m² and 63 ± 33 ml/min/1.73 m², p = 0.566), but both patient groups had a lower eGFR compared to healthy controls (87 ± 13 ml/min/1.73 m², p = 0.013 and p = 0.011, respectively). Among ADPKD patients, 12 received metoprolol, 14 amiodipine, and 2 no antihypertensive treatment. Among non-ADPKD patients, 5 received metoprolol, 5 amiodipine, and 6 no antihypertensive treatment. Overall, more antihypertensive treatment was needed in the ADPKD group.

In Group 2, 10 patients had a renal biopsy and 6 patients had no biopsy. The primary kidney disease was chronic nonspecified glomerulonephritis in 5 patients, chronic interstitial nephritis in 2 patients, and focal segmental glomerulosclerosis (FSGS) in 3 patients.

4.2. Weight Increase, Water Intake, and Total Urine Output. The three groups’ water intake was similar (1699 ± 437 ml in ADPKD patients vs. 1497 ± 253 ml in non-ADPKD patients, p = 0.106, and 1472 ± 189 ml in healthy controls, p = 0.055 compared to ADPKD patients, and p = 0.748 compared to non-ADPKD patients).

Table 1: Baseline demographics of the participants in the study.

|                              | ADPKD Patients | Non-ADPKD Patients | Controls |
|------------------------------|----------------|--------------------|----------|
| Number of subjects (n)       | 18             | 16                 | 18       |
| Age (years)                  | 55 ± 13        | 56 ± 17            | 55 ± 15  |
| Gender (men/women)           | 9/9            | 9/7                | 8/10     |
| Office systolic bBP (mmHg)   | 137 ± 16*      | 130 ± 16           | 125 ± 10 |
| Office diastolic bBP (mmHg)  | 79 ± 10#       | 72 ± 9             | 74 ± 7   |
| eGFR (ml/min/17.3 m²)        | 69 ± 27*       | 63 ± 33*           | 87 ± 13  |
| p-Creatinine (µmol/l)        | 107 ± 44*      | 124 ± 57*          | 76 ± 11  |
| u-Albumin (mg/l)             | 17 [8; 50]*    | 81 [26; 283]*      | 8 [3, 11]|

Patients with adult dominant polycystic kidney disease (ADPKD), patients with non-ADPKD kidney disease (non-ADPKD), and healthy control subjects (controls). Values represent n in either group or mean ± SD or median with 25% and 75% percentiles in brackets. *p < 0.05 between ADPKD or non-ADPKD patients and healthy controls. $p < 0.05 between ADPKD and non-ADPKD patients. ADPKD = patients with adult dominant polycystic kidney disease; non-ADPKD = patients with non-ADPKD kidney disease; controls = healthy control subjects. bBP = brachial blood pressure; eGFR = estimated glomerular filtration rate.
All three groups had a similar increase in body weight one hour after water intake compared to baseline (the increase was $1.4 \pm 0.5$ kg in ADPKD patients vs. $1.5 \pm 0.3$ kg in non-ADPKD patients, $p = 0.727$ and $1.3 \pm 0.3$ kg in healthy controls, $p = 0.676$ compared to ADPKD patients, and $p = 0.288$ compared to non-ADPKD patients). Total urine output in period 3–7 was $1827 \pm 553$ ml in ADPKD patients, $1568 \pm 370$ ml in non-ADPKD patients, and $1739 \pm 397$ ml in healthy controls ($p = 0.122$ when comparing ADPKD with non-ADPKD patients, $p = 0.585$ when comparing ADPKD with healthy controls, and $p = 0.205$ when comparing non-ADPKD with healthy controls).

4.3. Renal Water Excretion. $C_{H2O}$, UO, u-Osm, p-Osm, and u-AQP2 are presented in Table 2. Means of $C_{H2O}$ and u-AQP2 are given in Figures 1(a) and 1(b).

For $C_{H2O}$, comparison within groups showed that $C_{H2O}$ increased rapidly after water load and peaked in Period 4 in all groups. Comparison between the three groups showed that in Period 3, the ADPKD patients had an increased $C_{H2O}$ compared to non-ADPKD patients ($2.97 \pm 2.42$ ml/min in ADPKD patients vs. $1.31 \pm 1.50$ ml/min in non-ADPKD patients, $p = 0.029$), but no difference existed between ADPKD or non-ADPKD patients and controls ($p = 0.526$ and $p = 0.177$, respectively). In Period 4, we saw a lower increase in non-ADPKD patients compared to healthy controls ($5.6 \pm 3.7$ ml/min in non-ADPKD patients vs. $8.3 \pm 3.5$ ml/min in healthy controls, $p = 0.043$). There was no significant difference between non-ADPKD and ADPKD patients ($p = 0.605$) or ADPKD patients and healthy controls ($p = 0.175$). In Period 7, all three groups had similar $C_{H2O}$ levels compared to baseline ($C_{H2O}$ differed with $0.9 \pm 1.9$ within ADPKD patients, $1.2 \pm 1.4$ ml/min within non-ADPKD patients and $0.6 \pm 1.4$ ml/min within healthy controls, $p > 0.05$ for all).

For UO, comparison within groups showed that UO increased rapidly after water loading and peaked in Period 4 in all groups. Comparison between groups showed that ADPKD patients had an increased UO compared to non-ADPKD patients in Period 2 ($9.7 \pm 9.2$ ml/min in ADPKD patients vs. $5.95 \pm 18.7$ ml/min in non-ADPKD patients, $p = 0.028$, and vs. $639 \pm 209$ ml/min in healthy controls, $p = 0.007$). In Period 3, U-Osm remained lower in ADPKD than in non-ADPKD patients ($p = 0.023$). In Period 7, U-Osm was significantly more decreased compared to baseline (Period 2) in ADPKD patients than in non-ADPKD patients (the decrease between Periods 2 and 7 was $150 \pm 175$ mosmol/kg in ADPKD patients vs. $288 \pm 186$ mosmol/kg in non-ADPKD patients, $p = 0.034$, and $220 \pm 248$ mosmol/kg in healthy controls, $p = 0.341$ compared to ADPKD patients and $p = 0.383$ compared to non-ADPKD patients, respectively).

Comparison within groups showed that p-Osm and p-AVP were similar between the three groups throughout the examination day ($p = 0.758$ and $p = 0.866$, respectively). In addition, p-Osm and p-AVP did not deviate significantly during the test although there was a clear tendency to a decrease in p-Osm ($p = 0.075$ for p-Osm and $p = 0.243$ for p-AVP). However, the decrease in p-Osm between Period 2 and Period 6 was more pronounced in the two patient groups compared to healthy controls ($4.4 \pm 2.9$ mosmol/kg in ADPKD patients and $4.4 \pm 3.2$ mosmol/kg in non-ADPKD patients vs. $2.2 \pm 2.5$ mosmol/kg in healthy controls, $p = 0.038$ and $p = 0.025$, respectively).

The U-AQP2 excretion rate decreased to a very low level in all three groups with the lowest level in Periods 4 and 5. There was a very small difference between the groups in Period 4, where non-ADPKD patients had an higher u-AQP2 excretion rate compared to healthy controls ($0.02 [0.01; 0.09]$ vs. $0.01 [0.00; 0.02]$, $p = 0.023$).

4.4. Renal Sodium Excretion. $F_{ENa}$ and u-ENaC are given in Table 3, and the means are given in Figures 1(c) and 1(d).

Comparison within groups showed an increase in $F_{ENa}$ to a maximum level in Period 4 in all groups. Although a considerable variation existed between the groups, the relative increase was approximately the same in all three groups, i.e., a doubling. U-ENaC decreased to very low levels in all groups in Period 4 and remained low during the following periods.

Comparison between groups showed that $F_{ENa}$ was increased in the two patients groups compared to healthy controls in Period 2 ($0.92 \pm 0.60$ % in ADPKD patients, $1.09 \pm 0.72$ in non-ADPKD patients vs. $0.51 \pm 0.24$ % in healthy controls, $p = 0.013$ and $p = 0.006$, respectively). This difference remained during the dilution test.

The U-ENaC excretion rate decreased to a very low level in all three groups with the lowest level in Periods 4 and 5. However, ADPKD patients had a lower decrease in u-ENaC excretion rate compared to non-ADPKD patients and healthy controls, when comparing the decrease between Period 2 and Period 4 ($0.5 [0.3; 1.0]$ ng/min in ADPKD patients vs. $0.8 [0.6; 1.5]$ ng/min in non-ADPKD patients, $p = 0.042$ and $0.9 [0.6; 2.9]$ ng/min in healthy controls, $p = 0.029$).

4.5. Renal Albumin Excretion and Creatinine Clearance. $C_{Cr}$ and u-Alb are presented in Table 3.

$C_{Cr}$ was similar throughout the examination day in all three groups ($p = 0.204$). $C_{Cr}$ was decreased in non-ADPKD patients compared to healthy controls throughout the examination day ($p < 0.05$ in all periods), but not when comparing ADPKD patients to healthy controls ($p = NS$ in all periods). However, we did not measure any significant difference in $C_{Cr}$ between ADPKD patients and non-ADPKD patients throughout the examination day ($p = NS$ in all periods).
Table 2: Renal water excretion during the water loading test in patients with adult dominant polycystic kidney disease (ADPKD), patients with non-ADPKD kidney disease (non-ADPKD), and healthy control subjects (controls).

| Time | Baseline | Period 1 | Period 2 | Period 3 | Period 4 | Period 5 | Period 6 | Period 7 |
|------|----------|----------|----------|----------|----------|----------|----------|----------|
|      |          | 07.30 AM | 07.30 AM | 08.30 AM | 09.30 AM | 10.30 AM | 11.30 AM | 00.30 PM |
|      |          | –07.30 AM| –08.30 AM| –09.30 AM| –10.30 AM| –11.30 AM| –00.30 AM| –01.30 PM|
| C42O (ml/min) | ADPKD | (-0.52 ± 0.91) | (-0.52 ± 0.92) | 2.97 ± 2.42 | 5.80 ± 4.09 | 4.55 ± 2.25 | 1.77 ± 2.27 | 0.40 ± 1.71 |
|      | Non-ADPKD | (-0.79 ± 0.81) | (-0.85 ± 0.61) | 1.31 ± 1.50 | 4.71 ± 3.38 | 3.41 ± 1.86 | 1.59 ± 1.47 | 0.37 ± 1.34 |
|      | Controls | (-0.83 ± 0.45) | (-0.97 ± 0.70) | 2.40 ± 2.71 | 6.89 ± 3.50 | 4.68 ± 2.27 | 1.22 ± 1.57 | (-0.14 ± 1.59) |

Comparison within groups: 0.200
Comparison between groups: 0.023

U-Osm (mosmol/kg) | ADPKD | 485.6 ± 136.0 | 463.4 ± 149.1 | 199.7 ± 87.9 | 96.1 ± 25.7 | 111.0 ± 38.1 | 209.7 ± 106.6 | 313.2 ± 136.6 |
|      | Non-ADPKD | 568.8 ± 251.6 | 595.9 ± 187.3 | 287.3 ± 125.0 | 118.5 ± 43.8 | 126.1 ± 28.4 | 207.7 ± 92.9 | 307.8 ± 138.3 |
|      | Controls | 538.3 ± 162.4 | 639.5 ± 209.4 | 235.4 ± 145.2 | 95.9 ± 41.7 | 113.7 ± 60.8 | 231.8 ± 143.5 | 403.7 ± 182.7 |

Comparison within groups: 0.065
Comparison between groups: 0.055

P-Osm (mosmol/kg) | ADPKD | 292 ± 4 | 286 ± 5 | 286 ± 3 | 288 ± 4 | 288 ± 4 | 288 ± 4 | 288 ± 4 |
|      | Non-ADPKD | 293 ± 6 | 287 ± 5 | 287 ± 4 | 289 ± 5 | 289 ± 5 | 289 ± 5 |
|      | Controls | 292 ± 3 | 285 ± 4 | 286 ± 3 | 289 ± 4 | 290 ± 4 | 290 ± 4 |

Comparison within groups: X
Comparison between groups: 0.758

U-AQP2 excretion rate (ng/min) | ADPKD | 0.70 [0.38; 1.20] | 0.69 [0.39; 1.32] | 0.11 [0.03; 0.17] | 0.12 [0.01; 0.06] | 0.02 [0.01; 0.03] | 0.06 [0.03; 0.13] | 0.15 [0.06; 0.27] |
|      | Non-ADPKD | 0.75 [0.49; 1.58] | 1.12 [0.66; 1.45] | 0.17 | 0.09 [0.05] | 0.05 [0.03] | 0.10 | 0.20 |
|      | Controls | 0.69 [0.45; 1.01] | 1.29 [0.50; 2.34] | 0.03 [0.02; 0.13] | 0.01 [0.00; 0.02] | 0.01 [0.01; 0.03] | 0.05 [0.03; 0.23] | 0.13 |

Kruskal-Wallis test: 0.872
Comparison within groups: X
Comparison between groups: 0.758

UO (ml/min) | ADPKD | 1.57 ± 1.07 | 1.89 ± 1.61 | 6.50 ± 3.77 | 9.09 ± 4.89 | 7.33 ± 2.52 | 4.29 ± 2.55 | 2.80 ± 1.87 |
|      | Non-ADPKD | 1.13 ± 0.39 | 0.99 ± 0.36 | 4.47 ± 2.18 | 8.06 ± 3.63 | 6.09 ± 2.35 | 4.07 ± 1.42 | 2.89 ± 1.26 |
|      | Controls | 1.16 ± 0.45 | 1.08 ± 0.63 | 5.55 ± 3.31 | 9.92 ± 4.13 | 7.35 ± 2.27 | 3.71 ± 1.43 | 2.35 ± 1.66 |

Comparison within groups: 0.299
Comparison between groups: 0.157

An oral water load of 20 ml/body weight was given immediately after period 2. Urine was collected in seven periods. Period 1 (24 hours): from 07.30 AM the day before arrival to the laboratory to 07.30 AM on the examination day. Period 2 (one hour): 07.30–08.30 AM. Period 3 (one hour): 08.30–09.30 AM. Period 4 (one hour): 09.30–11.30 AM. Period 5 (one hour): 10.30–11.30 AM. Period 6 (one hour): 11.30–00.30 PM. Period 7 (one hour): 00.30–01.30 PM. A general linear model with Greenhouse-Geisser correction was used for comparison within and between the three groups. Values represent mean ± SD or median with 25% and 75% percentiles in brackets. *p < 0.05 between ADPKD or Non-ADPKD patients and controls. #p < 0.05 between ADPKD and Non-ADPKD patients. CH2O = free water clearance. U-AQP2 = urinary aquaporin-2, Osm = osmolality. UO = urine output.

4.6. Vasoactive Hormones. AVP, PRC, Aldo, and AngII are presented in Table 4.

There were no significant differences in p-AVP, PRC and p-AngII either within or between the three groups during the water dilution test.

P-Aldo was increased in ADPKD patients compared to healthy controls at baseline but not compared to non-
ADPKD patients (250 ± 115 in ADPKD patients vs. 167 ± 49 in healthy controls, p = 0.009 and 203 ± 147 in non-ADPKD patients, p = 0.301). The increased p-Aldo in ADPKD patients compared to healthy controls remained after water load (p = 0.018).

4.7. Systemic Haemodynamics. Systolic bBP, diastolic bBP, MAP, heart rate, systolic cBP, diastolic cBP, Aix, and PWV are presented in Table 5.

Systolic bBP was higher at baseline (Period 2) in the two patient groups compared to healthy controls (129 ± 11 mm
Patients had an increased systolic cBP compared to healthy the examination day (*p* < 0.053). Most likely by

**5. Discussion**

The present paper compares urine dilution ability, tubular function, vasoactive hormones, and systemic hemodynamics in ADPKD patients, non-ADPKD patients with chronic kidney
After water loading, the ADPKD patients had an increased CH₂O compared to non-ADPKD patients. This means a faster elimination of excess water in ADPKD patients than in non-ADPKD patients. Although urine diluting ability tended to be higher in healthy controls, it did not deviate significantly from patients with ADPKD, but it was significantly better than in non-ADPKD patients. Not surprisingly, these results are in good agreement with measurements of u-Osm, which was reduced to approximately the same degree in ADPKD patients and healthy controls.

The final regulation of renal water and sodium excretion occurs in the distal part of the nephron. The main tubular transporters of water and sodium are the aquaporin2 water channels regulated by vasopressin, and the epithelial sodium channels regulated by mineralocorticoids via the mineralocorticoid receptor, respectively. Abnormal function is well documented of both the osmoregulatory system and the renin-angiotensin-aldosterone system in heart failure, liver disease, and chronic renal disease. In the present study, our focus has been to measure the distal tubular function during water loading in ADPKD and non-ADPKD with mild to moderate reduced renal function. We used modern methods to reflect the activity in the aquaporin2 water channels (u-AQP2) and the epithelial sodium channels (u-ENaC). We wanted to clarify whether the different pathophysiological mechanisms in progression of kidney disease in ADPKD and non-ADPKD also resulted in different function of the distal tubules regarding sodium and water transportation.

5.1. Renal Water Excretion. After water loading, the ADPKD patients had an increased C₁₂H₂O compared to non-ADPKD patients. This means a faster elimination of excess water in ADPKD patients than in non-ADPKD patients. Although urine diluting ability tended to be higher in healthy controls, it did not deviate significantly from patients with ADPKD, but it was significantly better than in non-ADPKD patients. Not surprisingly, these results are in good agreement with measurements of u-Osm, which was reduced to approximately the same degree in ADPKD patients and healthy controls.

A previous study showed a decrease in p-Osm in CKD-patients after oral water loading with 20 ml/body weight [5]. In the present study, we also measured a larger decrease in p-Osm in the two patient groups compared to the controls. This confirms the reduced and slower ability to eliminate water in kidney disease.

U-AQP2 excretion rate decreased pronouncedly in all three groups after water loading to a very low level in all. Since u-AQP2 reflects water transport in the distal part of the nephron, our measurement is in good agreement with a very low or transitorily ceased water absorption in the final diluting part of the tubular system. We measured a small but significantly increased u-AQP2 in the non-ADPKD patients compared to healthy controls. This lack of reduction in u-AQP2 is in agreement with a reduced ability to increase water excretion in this group of patients as well.

Table 4: Hormones during urine dilution test in patients with adult dominant polycystic kidney disease (ADPKD), patients with non-ADPKD kidney disease (non-ADPKD), and healthy control subjects controls.

| Table 4: Hormones during urine dilution test in patients with adult dominant polycystic kidney disease (ADPKD), patients with non-ADPKD kidney disease (non-ADPKD), and healthy control subjects controls. | Baseline | Period 2 | Period 4 | Period 6 | Period 7 |
|---|---|---|---|---|---|
| AVP (pg/ml) | ADPKD | 0.3 ± 0.2 | 0.2 ± 0.1 | 0.3 ± 0.2 | 0.3 ± 0.2 |
| Non-ADPKD | 0.4 ± 0.3 | 0.3 ± 0.2 | 0.3 ± 0.3 | 0.3 ± 0.2 | 0.3 ± 0.2 |
| Controls | 0.3 ± 0.1 | 0.2 ± 0.1 | 0.3 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.2 |
| Comparison between groups | 0.243 | | | | |
| Comparison within groups | 0.866 | | | | |
| PRC (pg/ml) | ADPKD | 7 [4, 9] | 6 [5, 8] | 7 [5, 8] | 5 [4, 9] |
| Non-ADPKD | 8 [5, 17] | 7 [5, 18] | 7 [5, 19] | 6 [4, 19] | 6 [3, 19] |
| Controls | 6 [4, 8] | 6 [4, 7] | 5 [3, 7] | 5 [3, 7] | 5 [3, 7] |
| Kruskal-Wallis test | 0.136 | 0.297 | 0.059 | 0.550 | 0.550 |
| AngII (pmol/l) | ADPKD | 5 ± 3 | 5 ± 3 | 5 ± 2 | 6 ± 3 |
| Non-ADPKD | 5 ± 3 | 5 ± 3 | 5 ± 2 | 6 ± 3 | 6 ± 3 |
| Controls | 5 ± 3 | 5 ± 4 | 6 ± 4 | 7 ± 4 | 7 ± 4 |
| Comparison between groups | 0.024 | | | | |
| Comparison within groups | 0.936 | | | | |
| Aldo (pg/ml) | ADPKD | 250 ± 115 | 235 ± 104 | 218 ± 134 | 238 ± 139 |
| Non-ADPKD | 203 ± 147 | 201 ± 140 | 174 ± 106 | 170 ± 92 | 170 ± 92 |
| Controls | 167 ± 49 | 154 ± 55 | 120 ± 47 | 136 ± 50 | 136 ± 50 |
| Comparison between groups | 0.668 | | | | |
| Comparison within groups | 0.025 | | | | |

An oral water load of 20 ml/body weight was given immediately after period 2. Urine was collected in seven periods. Period 1 (24 hours): from 07.30 AM the day before arrival to the laboratory to 07.30 AM on the examination day. Period 2 (one hour): 07.30–08.30 AM. Period 3 (one hour): 08.30–09.30 AM. Period 4 (one hour): 09.30–11.30 AM. Period 5 (one hour): 10.30–11.30 AM. Period 6 (one hour): 11.30–00.30 PM. Period 7 (one hour): 00.30–01.30 PM. A general linear model with Greenhouse-Geisser correction was used for comparison within and between the three groups. Values represent mean ± SD or median with 25% and 75% percentiles in brackets. *p < 0.05 between ADPKD or Non-ADPKD patients and controls. †p < 0.05 between ADPKD and Non-ADPKD patients. AngII = plasma angiotensin II concentration. Aldo = plasma aldosterone concentration.
Table 5: Hemodynamics during the urine dilution test in patients with adult dominant polycystic kidney disease (ADPKD), patients with non-ADPKD kidney disease (non-ADPKD), and healthy control subjects (controls).

|                     | Baseline Period 2 | Period 3 | Period 4 | Period 5 | Period 6 | Period 7 |
|---------------------|-------------------|----------|----------|----------|----------|----------|
| **Systolic bBP (mm Hg)** |                   |          |          |          |          |          |
| ADPKD               | 128.5 ± 11.3*     | 141.0 ± 13.4* | 133.0 ± 11.8* | 128.9 ± 10.1* | 128.5 ± 11.0* | 132.1 ± 13.9* |
| Non-ADPKD           | 124.9 ± 14.0*     | 138.5 ± 15.5* | 131.4 ± 14.1* | 129.2 ± 11.4* | 129.2 ± 11.7* | 133.0 ± 12.4* |
| Controls            | 114.7 ± 12.7      | 126.1 ± 14.9 | 121.4 ± 13.2 | 121.7 ± 14.3 | 119.5 ± 13.6 | 121.7 ± 15.5 |
| **Comparison between groups** | 0.562 |          |          |          |          |          |
| **Comparison within groups** | <0.001 |          |          |          |          |          |
| ADPKD               | 83.0 ± 8.3*       | 90.2 ± 10.3* | 86.1 ± 10.6*# | 83.4 ± 8.3*# | 82.1 ± 7.8* | 83.6 ± 8.7* |
| Non-ADPKD           | 78.7 ± 8.3        | 87.1 ± 7.5*  | 82.2 ± 7.4*  | 79.5 ± 6.3  | 79.5 ± 8.4  | 80.7 ± 7.1* |
| Controls            | 74.4 ± 9.6        | 81.7 ± 11.7 | 77.8 ± 10.7 | 76.7 ± 11.0 | 75.8 ± 10.5 | 76.3 ± 11.7 |
| **Comparison within groups** | 0.306 |          |          |          |          |          |
| **Comparison between groups** | <0.001 |          |          |          |          |          |
| MAP (mm Hg)         | 103.9 ± 10.3*     | 113.4 ± 10.5* | 107.5 ± 10.0* | 104.3 ± 8.2* | 103.3 ± 8.6* | 105.8 ± 9.7* |
| Non-ADPKD           | 99.9 ± 10.3       | 110.6 ± 10.3* | 104.7 ± 9.7* | 102.2 ± 7.8* | 102.2 ± 9.4* | 104.7 ± 8.9* |
| Controls            | 92.8 ± 10.7       | 102.8 ± 12.8 | 96.9 ± 11.1 | 97.4 ± 12.1 | 95.8 ± 11.4 | 97.2 ± 12.9 |
| **Comparison within groups** | 0.347 |          |          |          |          |          |
| **Comparison between groups** | <0.001 |          |          |          |          |          |
| HR (beats/min)      | 60.3 ± 9.5        | 60.4 ± 9.5*# | 61.2 ± 10.1*# | 62.1 ± 9.9*# | 61.3 ± 10.2 | 62.2 ± 9.0 |
| Non-ADPKD           | 58.5 ± 8.2        | 56.0 ± 6.5  | 57.7 ± 6.4  | 59.0 ± 7.5  | 60.4 ± 7.3  | 62.2 ± 7.5 |
| Controls            | 56.8 ± 7.4        | 54.8 ± 7.3  | 55.9 ± 7.4  | 56.6 ± 6.9  | 58.8 ± 6.7  | 59.5 ± 6.9 |
| **Comparison within groups** | 0.671 |          |          |          |          |          |
| **Comparison between groups** | 0.417 |          |          |          |          |          |
| Systolic cBP (mm Hg) | 119.6 ± 13.4*     | 131.3 ± 15.1*# | 122.7 ± 13.0* | 120.0 ± 9.9* | 119.2 ± 12.8* | 122.7 ± 14.2* |
| Non-ADPKD           | 114.6 ± 13.2      | 124.0 ± 12.5 | 119.2 ± 11.2* | 117.8 ± 9.7 | 117.3 ± 11.5 | 122.3 ± 10.5* |
| Controls            | 106.9 ± 12.6      | 117.8 ± 13.3 | 113.4 ± 13.0 | 114.4 ± 14.5 | 112.6 ± 13.8 | 115.2 ± 15.7 |
| **Comparison within groups** | 0.730 |          |          |          |          |          |
| **Comparison between groups** | <0.001 |          |          |          |          |          |
| Diastolic cBP (mm Hg) | 83.7 ± 8.1*       | 91.7 ± 9.8* | 87.1 ± 10.1*# | 84.4 ± 8.8*# | 83.3 ± 7.9* | 84.5 ± 8.6* |
| Non-ADPKD           | 79.2 ± 8.9        | 87.8 ± 7.4*  | 82.6 ± 7.5*  | 80.2 ± 6.0  | 80.2 ± 8.6  | 82.1 ± 7.5* |
| Controls            | 75.2 ± 9.7        | 82.3 ± 12.1 | 78.7 ± 10.9 | 77.2 ± 11.2 | 76.5 ± 10.5 | 77.3 ± 12.0 |
| **Comparison within groups** | 0.770 |          |          |          |          |          |
| **Comparison between groups** | <0.001 |          |          |          |          |          |
| Alx (%)             | 31.9 ± 9.8        | 33.7 ± 10.9 | 30.5 ± 13.5 | 30.1 ± 15.6 | 30.9 ± 14.1 | 30.4 ± 15.3 |
| Non-ADPKD           | 32.7 ± 17.8       | 33.2 ± 13.7 | 31.1 ± 14.6 | 30.9 ± 15.5 | 30.3 ± 15.6 | 28.6 ± 14.9 |
| Controls            | 30.1 ± 13.0       | 31.0 ± 14.2 | 31.0 ± 13.5 | 29.7 ± 14.0 | 27.8 ± 13.3 | 25.9 ± 14.4 |
| **Comparison within groups** | 0.212 |          |          |          |          |          |
| **Comparison between groups** | 0.013 |          |          |          |          |          |
| PWV (m/s)           | 8.0 ± 1.7         | 8.4 ± 1.9   | 8.2 ± 1.8   | 8.1 ± 1.8   | 8.1 ± 1.8   | 8.2 ± 1.8   |
| Non-ADPKD           | 8.2 ± 2.2         | 8.5 ± 2.2   | 8.2 ± 2.1   | 8.3 ± 2.0   | 8.2 ± 2.0   | 8.4 ± 2.1   |
| Controls            | 7.8 ± 1.8         | 8.1 ± 1.7   | 8.0 ± 1.7   | 8.0 ± 1.7   | 7.9 ± 1.7   | 8.0 ± 1.9   |
| **Comparison within groups** | 0.852 |          |          |          |          |          |
| **Comparison between groups** | 0.100 |          |          |          |          |          |

An oral water load of 20 ml/body weight was given immediately after period 2. Urine was collected in seven periods. Period 1 (24 hours): from 07.30 AM the day before arrival to the laboratory to 07.30 AM on the examination day. Period 2 (one hour): 07.30–08.30 AM. Period 3 (one hour): 08.30–09.30 AM. Period 4 (one hour): 09.30–11.30 AM. Period 5 (one hour): 10.30–11.30 AM. Period 6 (one hour): 11.30–00.30 PM. Period 7 (one hour): 00.30–01.30 PM. A general linear model with Greenhouse-Geisser correction was used for comparison within and between the three groups. Values represent mean ± SD or median with 25% and 75% percentiles in brackets * p < 0.05 between ADPKD or non-ADPKD patients and healthy controls. # p < 0.05 between ADPKD and non-ADPKD patients. bBP = brachial blood pressure, MAP = mean arterial pressure, HR = heart rate, cBP = central blood pressure, AIx = augmentation index, PWV = pulse wave velocity.

demonstrated in measurements of free water clearance. The u-AQP2 levels were very low in all three groups during the test, and in cannot be excluded that the difference is by chance. Although eGFR was the same in the two groups of patients, there was a tendency to a lower creatinine clearance in the non-ADPKD patients compared to ADPKD patients. Thus, the lower u-AQP2 in non-ADPKD patients may reflect a slightly lower renal function in non-ADPKD patients and consequently a lower ability to reduce u-AQP2.
5.2. Renal Sodium Excretion. FE\textsubscript{Na} increased in all three groups during the urine diluting test, and as expected, it was at a significantly higher level in the two patient groups than in the controls. U-ENaC reflected sodium transport via the epithelial sodium channels in the distal part of the nephron. Although u-ENaC was reduced in all three groups, the reduction was more pronounced in healthy controls and ADPKD patients than in non-ADPKD patients. As for u-AQP2, this suggests a lower tubular response in non-ADPKD patients compared with the other groups. Of course, this difference may be by chance due to the very low levels of u-ENaC, but it could also be attributed to the fact that non-ADPKD had the lowest renal function, when estimated by creatinine clearance as for the low level of u-AQP2.

5.3. Creatinine Clearance and Albumin Excretion. The study was designed to have two patient groups with the same degree of reduction in renal function. This was also obtained when looked at eGFR. However, during measurement of creatinine clearance during the study, the renal function was significantly lower in non-ADPKD than in control subjects and tended to be lower than in ADPKD patients. A lower creatinine clearance in the non-ADPKD group may contribute to the measured lower urine diluting ability in the non-ADPKD group compared to the other groups. This may also be in good agreement with the slightly higher urine excretion of albumin in non-ADPKD patients, but the levels of urine albumin excretion were very low in all three groups from Period 3 and during the test. Thus, conclusions cannot be drawn about albumin excretion during the diluting test.

5.4. Vasoactive Hormones. We found no significant changes in PRC, p-AngII, or p-Aldo which could explain the changes in urinary excretion of water and sodium between the groups during the urine diluting test. P-Aldo was increased in ADPKD patients compared to healthy controls at baseline and after water loading. This is in agreement with previous studies that have showed activation of the RAAS-system in CKD, including ADPKD [17–19]. P-AVP was expected to fall during water loading. We measured a tendency to a reduction p-AVP in both healthy controls and ADPKD patients, but no significant changes, which is in agreement with a previous study with healthy subjects [20]. The reason might be that the subjects did not thirst up to the water loading test. Thus, vasopressin secretion was not stimulated before the test. Another explanation might be that the patients had on average a relatively well preserved renal function with eGFR in the range 60–70 ml/min/1.73 m\textsuperscript{2}.

5.5. Systemic Haemodynamics. Blood pressure is a known factor to influence kidney function [21]. Blood pressure was slightly elevated in the two groups of patients. However, we measured no clinical significant changes either within or between the three groups regarding brachial or central blood pressure. Thus, a possible influence of blood pressure on the results of the urine dilution test is estimated to be absent or minimal.

6. Strengths and Limitations

The three groups had similar age and gender segregation and digested similar amount of water during the water loading. Furthermore, the two patient groups had similar eGFR, which was significantly decreased compared with healthy controls. This match is a strength in our study as well as the length and uniform procedure of the dilution test. However, during the study, the values of creatinine clearances tended to be systematically lower in non-ADPKD than in ADPKD patients. Although no significant differences existed between the two groups of patients, we must accept this lack of concordance between eGFR and creatinine clearance as a weakness. We did not find it ethically justified to discontinue antihypertensive medication. Therefore, patients received antihypertensive treatment during the study, but it was standardized to only metoprolol and/or amlodipine, and a possible influence of antihypertensive treatment on the results is estimated to be absent or minimal during the urine dilution test.

7. Conclusion

ADPKD patients had a higher free water clearance than non-ADPKD patients during a water loading test, and urinary excretion of both AQP2 and ENaC was more rapidly reduced than in non-ADPKD patients. Thus, urine-diluting capacity may be better preserved in patients with ADPKD than in patients with other chronic kidney diseases having the same degree of reduction in renal function.

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| ALAT         | Alanine-amino-transaminase |
| Alx          | Augmentation index |
| ADPKD        | Autosomal dominant polycystic kidney disease |
| AQP2         | Aquaporin-2 |
| bBP          | Brachial blood pressure |
| cBP          | Central blood pressure |
| C\textsubscript{Cr} | Creatinine clearance |
| C\textsubscript{H2O} | Free water clearance |
| CKD          | Chronic kidney disease |
| eGFR         | Estimated glomerular filtration rate |
| ENaC         | Epithelial sodium channel |
| FE\textsubscript{Na} | Fractional excretion of sodium |
| HbA1c        | Glycosylated hemoglobin A1c |
| MAP          | Mean arterial pressure |
| Non-ADPKD    | Patients with chronic kidney disease except ADPKD |
| ADPKD        | ADPKD |
| p            | p value |
| p-Aldo       | Plasma aldosterone |
| p-AngII      | Plasma angiotensin |
| p-AVP        | Plasma vasopressin |
| P-Osm        | Plasma osmolality |
| PRC          | Plasma renin concentration |
Acknowledgments
We thank laboratory technicians, Anne Mette Ravn, Henriette Vorup Simonsen, and Kirsten Nygaard, for their skillful assistance.

References

[1] R. L. Jamison and R. E. Oliver, “Disorders of urinary concentration and dilution,” *The American Journal of Medicine*, vol. 72, no. 2, pp. 308–322, 1982.

[2] J. D. Holfert, R. A. Fenton, H. B. Moeller et al., “Vasopressin-stimulated increase in phosphorylation at Ser269Potentiates plasma membrane retention of aquaporin-2,” *Journal of Biological Chemistry*, vol. 283, no. 36, pp. 24617–24627, 2008.

[3] S. Nielsen, J. Frøkjaer, D. Marples, T.-H. Kwon, P. Agre, and M. A. Knepper, “Aquaporins in the kidney: from molecules to medicine,” *Physiological Reviews*, vol. 82, no. 1, pp. 205–244, 2002.

[4] B. B. Davis and T. V. Zenser, “Evaluation of renal concentrating and diluting ability,” *Clinics in Laboratory Medicine*, vol. 13, no. 1, pp. 131–134, 1993.

[5] E. B. Pedersen, I. M. Thomsen, and T. G. Lauridsen, “Abnormal function of the vasopressin-cyclic-AMP-aquaporin2 axis during urine concentrating and diluting in patients with reduced renal function. A case control study,” *BMC Nephrology*, vol. 11, p. 26, 2010.

[6] V. E. Torres, P. C. Harris, and Y. Pirson, “Autosomal dominant polycystic kidney disease,” *The Lancet*, vol. 369, no. 9569, pp. 1287–1301, 2007.

[7] R. W. Schrier, G. Brosnaham, M. A. Cadnapaphornchai et al., “Predictors of autosomal dominant polycystic kidney disease progression,” *Journal of the American Society of Nephrology*, vol. 25, no. 11, pp. 2399–2418, 2014.

[8] A. Nakajima, Y. Lu, H. Kawano, S. Horie, and S. Muto, “Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD),” *Clinical and Experimental Nephrology*, vol. 19, no. 6, pp. 1199–1205, 2015.

[9] X. Wang, Y. Wu, C. J. Ward, P. C. Harris, and V. E. Torres, “Vasopressin directly regulates cyst growth in polycystic kidney disease,” *Journal of the American Society of Nephrology*, vol. 19, no. 1, pp. 102–108, 2008.

[10] T. Yamaguchi, J. C. Pelling, N. T. Ramaswamy et al., “cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway,” *Kidney International*, vol. 57, no. 4, pp. 1460–1471, 2000.

[11] M. H. Malmberg, F. H. Mose, E. B. Pedersen, J. N. Bech et al., “Urinary concentration ability is reduced to the same degree in adult dominant polycystic kidney disease compared with other chronic kidney diseases in the same CKD-stage and lower THAN in healthy control subjects—a CASE control study,” *BMC Nephrology*, vol. 21, no. 1, p. 379, 2020.

[12] D. Ravine, L. Sheffield, D. M. Danks, R. N. Gibson, R. G. Walker, and P. Kincaid-Smith, “Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1,” *The Lancet*, vol. 343, no. 8901, pp. 824–827, 1994.

[13] R. S. Pedersen, H. Bentzen, J. N. Bech, and E. B. Pedersen, “Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans,” *American Journal of Physiology-Renal Physiology*, vol. 303, no. 1, pp. F416–F427, 2012.

[14] C. C. Graffe, J. N. Bech, and E. B. Pedersen, “Effect of high and low sodium intake on urinary aquaporin-2 excretion in healthy humans,” *American Journal of Physiology-Renal Physiology*, vol. 302, no. 2, pp. F264–F275, 2012.

[15] S. K. Matthesen, T. Larsen, T. G. Lauridsen et al., “Effect of amiloride and spironolactone on renal tubular function, ambulatory blood pressure, and pulse wave velocity in healthy participants in a double-blind, randomized, placebo-controlled, crossover trial,” *Clinical and Experimental Hypertension*, vol. 34, no. 8, pp. 588–600, 2012.

[16] S. Al Therwani, M. E. S. Malmberg, J. R. Rosenbaek et al., “Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study,” *BMC Nephrology*, vol. 18, no. 1, p. 268, 2017.

[17] T. Berl, F. H. Katz, W. L. Henrich, A. de Torrente, and R. W. Schrier, “Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure,” *Kidney International*, vol. 14, no. 3, pp. 228–235, 1978.

[18] A. B. Chapman, A. Johnson, P. A. Gabow, and R. W. Schrier, “The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease,” *New England Journal of Medicine*, vol. 323, no. 16, pp. 1091–1096, 1990.

[19] R. J. Hené, P. Boer, H. A. Koomans, and E. J. Dorhout Mees, “Plasma aldosterone concentrations in chronic renal disease,” *Kidney International*, vol. 21, no. 1, pp. 98–101, 1982.

[20] R. S. Pedersen, H. Bentzen, J. N. Bech, O. Nyvad, and R. G. Walker, “The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease 1,” *Kidney International*, vol. 21, no. 1, p. 379, 2020.

[21] S. M. Hamrahian and B. Falkner, “Hypertension in chronic kidney disease,” *Advances in Experimental Medicine and Biology*, vol. 724, pp. 588–600, 2012.